Search Thermo Fisher Scientific
Hallmarks of Cancer ELISA Kits and Multiplex Immunoassays |
Thermo Fisher Scientific offers a wide variety of immunoassays for cancer progression research. ELISA kits and multiplex immunoassays allow for detection and characterization of soluble biomarkers involved with various hallmarks of cancer.
How many types of cancer have been identified by researchers? Hundreds. However, there are certain properties that all cancer cells have in common. We call them Hallmarks.
Thanks to PhD Sigrun Badrnya, you will be able to uncover hallmarks of cancer with multiplex gene and protein assays using Luminex technology.
Take advantage of this resource and watch this on demand webinar now.
Cancer is a leading cause of death worldwide and has become a major public health issue in the developed countries. Cancer development is a multistep process, during which the cells accumulate genetic abnormalities, especially in oncogenes and tumor suppressor genes, contributing to uncontrolled proliferation. These abnormalities provide several growth advantages. Indeed, the transformation from normal cell to tumor cell frequently involves mutations in the cell genome.
Hanahan and Weinberg described six key changes that occur during the transformation from a normal cell to a tumor cell; these features may be considered hallmarks of cancer. These comprise of sustaining proliferative signaling, evading growth suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, disrupting metabolism, and avoiding immune destruction [1] (Figure 1).
Four additional hallmarks and characteristics have been proposed by Hanahan, and these could be considered as part of the core hallmarks of cancer (Figure 1). More recently it has become evident that the cancer cell-derived extracellular vesicles/exosomes and their molecular cargo are implicated in almost all hallmarks of cancer as critical mediators of inter-cellular communication [1]. It has also been recognized that the tumor microenvironment plays a large critical part in tumorigenesis and malignant progression [2].
Figure 1. The biological processes established during the development of human tumors.
Expression of proliferation and survival signals by tumor cells allows them to grow continually as immortalized cells. To achieve growth independent of external growth factors, some tumor cells express activating mutations in proteins involved in cell growth. With a reduced dependence on exogenous growth signals, cancer cells can disrupt homeostasis and rapidly proliferate [3]. For example, ~50% of melanomas bear mutations in the gene coding for the serine-threonine kinase BRAF, and among these, about 90% are V600E point mutations [4].
With the ability to evade growth-inhibiting checkpoints, cancer cells can proliferate rapidly without suppression. Some of the most common tumor suppressants circumvented by cancer cells include signals of p53, retinoblastoma proteins, and transforming growth factor-beta (TGF-β) [5].
Retinoblastoma-associated proteins are responsible for regulating cells through growth-and-division cycles, whereas p53 proteins get signals from stress and abnormality sensors and can either halt cell-cycle progression or trigger apoptosis. In late-stage tumors, TGF-β can be found to activate cellular programs that confer traits to cancer cells associated with high-grade malignancy [1].
Approximately 90% of human cancer deaths are due to metastases, which are caused through invasion of adjacent tissues from the primary tumor site. A complex process, both invasion and metastasis involve utilizing changes in the physical coupling of cells to their environments and activation of extracellular proteases. Cell-cell adhesion molecules (CAMs), such as certain immunoglobulins, cadherins, and integrins, play a critical role in cancer cells invading and metastasizing new sites. E-cadherin is an example of a CAM that frequently observes downregulation and mutational inactivation in carcinomas [1].
A hallmark to many cancers, acquired resistance to apoptosis is a key feature in the survival and growth of cancer cells. Tumor cells limit apoptosis through the loss of p53 function, increased expression of antiapoptotic regulators or survival signals, or by downregulation of proapoptotic factors. This demonstrates that cancer cells operate diverse apoptosis-evading mechanisms during progression to malignancy [1].
Some targets associated in cell death include danger-associated molecular patterns which are released upon cell stress (HSP70, HSP90), HMGB1 in response to anti-cancer therapy and immunogenic cell death, and DKK1 which is secreted to regulate cell survival via the WNT signaling pathway.
Although not fully characterized, evading immunological destruction by T and B lymphocytes, macrophages, and natural killer (NK) cells is considered a new emerging hallmark of cancer. While the immune system acts as a significant barrier to tumor formation, under certain conditions (such as immunodeficient/immunocompromised state), the tumors can form more frequently and grow quicker. Furthermore, immunogenic cells can disable or paralyze T lymphocytes or NK cells—evading the immune system [1].
It has also been noted that certain inflammatory responses (such as infections or wound healing) have the inadvertent effect of supporting tumor functions. For example, inflammation can supply tumor microenvironments with growth and survival factors, and various enzymes that facilitate angiogenesis and aid in invasion and metastasis [1].
Some tumor cells overexpress vascular endothelial growth factor (VEGF), which is a major angiogenic factor. Secretion of angiogenic factors such as VEGF by tumor cells create blood vessels, which provide nutrients to the interior of tumors. These blood vessels are architecturally different from normal blood vessels being less organized. In order to grow, the tumors need to have blood supply to their interior, for delivery of nutrients and O2. The process of blood vessel growth is called angiogenesis, and most solid tumors secrete angiogenic factors [3].
Cancer cell-derived exosomes have emerged as a novel class of biomarkers playing a significant role in almost all hallmarks of cancer. As crucial mediators of inter-cellular communication, they transfer their molecular cargo from the releasing cell to the recipient cell. Recent advances have particularly focused on cancer cell-derived exosomes that contribute to tumorigenic and metastatic processes. This is achieved by shaping the tumor microenvironment, which is a valuable source of biomarkers in liquid biopsies [6].
Exosomes are secreted by almost all cell types, including cancerous cells. Tumor-derived exosomes have been reportedly involved in cancer malignancy by supporting proliferation, establishing pre-metastatic niches, and regulating drug resistance. They can also assist in the regulation and mediation of organotrophic metastasis, re-education of stromal cells, endocrine/paracrine induction of cancers, angiogenesis activation, immune system modulation, and remodeling of the extracellular matrix [6].
Learn more about cancer research areas and methods
ELISA enables the detection and measurement of a wide assortment of markers that fall within the hallmarks of cancer. This allows further investigation into cancer progression using various biological sources. We offer ELISA kits for the study of important targets that are useful for cancer research, from growth factors to immune-oncology checkpoints.
Invitrogen ELISA kits for popular targets such as EGF, IL-8, VEGF etc. are listed in Table 1. Standard curve of Human IL-8/NAP-1 using IL-8 Human ELISA Kit is shown in Figure 2.
Search cancer-related ELISA kits
Learn more about ELISA kits and components
Figure 2. Representative standard curve for Human IL-8/NAP-1 ELISA. ELISA was performed using human interleukin 8 (Hu IL-8) ranging from 0–1,000 pg/ml (0, 15.6, 31.2, 62.5, 125, 250, 500, and 1,000 pg/ml) and IL-8 Human ELISA Kit. Absorbance was measured at 450 nm and standard curve was plotted.
ProQuantum high-sensitivity immunoassays are designed for ease-of-use, high performance protein detection without the need for specialized instruments. Utilizing proximity-based amplification technology, these assays combine analyte specific high-affinity antibody-antigen binding with signal detection and amplification capabilities of qPCR to achieve a simple yet powerful next-generation protein quantitation platform.
These assays can be used to detect low target levels while using a smaller volume of sample, which is beneficial when handling limited precious samples. Invitrogen ProQuantum immunoassay kits for popular targets such as EGF, IL-8, c-Met etc. are listed in Table 2. Standard curve of EGF using EGF Human ProQuantum Immunoassay Kit is shown in Figure 3.
Find cancer-related ProQuantum assays
Learn more about how the ProQuantum immunoassays work
Read BioProbes Journal article: Introducing ProQuantum High-Sensitivity Immunoassays—The new generation of target-specific protein quantitation
Figure 3. Examples of Human EGF standard curve. The standard curve for EGF Human ProQuantum Immunoassay Kit shows a large dynamic range (0.00256–5,000 pg/mL) for EGF protein.
Invitrogen ProcartaPlex multiplex immunoassay panels provide a powerful biomarker detection tool to help distinguish diseased from non-diseased states and probe cellular processes involved with cancer progression. These Luminex xMAP-based assays allow for the simultaneous measurement and tracking of multiple soluble proteins and targets of interest over time to thoroughly understand markers in cancer development and metastasis. Various checkpoint markers in melanoma patient samples were measured using the ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex and ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex (Figure 4).
Select one of our preconfigured panels described in Table 3 or use the Panel Configurator below to customize your specific panel.
ProcartaPlex Panel Configurator
Learn more about ProcartaPlex multiplex immunoassays
Figure 4. Serum levels of checkpoint markers in melanoma patient samples. The ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex and ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex were used to measure various checkpoint markers in melanoma patient samples. Results are shown as the mean of ungrouped human samples for all targets of both the panels. Used with permission from Exner R., Sachet M., Arnold T., et al. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med, 2016. 5(9): 2350-8.
Sustaining Proliferative Signaling Panel | ||
---|---|---|
Product name | Size | Cat. No. |
ProcartaPlex Human Cell Proliferation Panel, 8plex Target list [bead region]: | 96 tests | EPX080-15844-901 |
Evading growth suppressors | ||
ProcartaPlex Human Growth Factor Panel, 11plex Target list [bead region]: | 96 tests | EPX110-12170-901 |
Activating invasion and apoptosis | ||
ProcartaPlex Human Cell Proliferation and Metastasis Panel 1, 13plex Target list [bead region]: | 96 tests | EPX130-15841-901 |
ProcartaPlex Human Cell Proliferation and Metastasis Panel 2, 12plex Target list [bead region]: beta-2-microglobulin (B2M) [21], cathepsin D [44], CEA (CEACAM-5) [52], EGFR (ErbB1) [37], haptoglobin [63], HGFR (c-Met) [25], IGFBP-2 [76], IGFBP-3 [13], MIA [75], MIP-4 (CCL18) [61], periostin (OSF-2) [62], VE-cadherin [28] | 96 tests | EPX120-15842-901 |
Resisting cell death | ||
ProcartaPlex Human Cell Death Panel, 4plex Target list [bead region]: | 96 tests | EPX040-15843-901 |
ProcartaPlex Human Apoptotic Cell Clearance Panel, 12plex Target list [bead region]: | 96 tests | EPX120-15816-901 |
Avoiding immune destruction/tumor promoting inflammation | ||
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex Target list [bead region]: | 96 tests | EPX14A-15803-901 |
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex Target list [bead region]: | 96 tests | EPX140-15815-901 |
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 3, 9plex Target list [bead region]: | 96 tests | EPX090-15820-901 |
Inducing Angiogenesis | ||
ProcartaPlex Human Angiogenesis Panel, 18plex Target list [bead region]: | 96 tests | EPX180-15806-901 |
ProcartaPlex Human Angiogenesis Panel 2, 3plex Target list [bead region]: | 96 tests | EPX030-15807-901 |
Cancer cell-derived exosomes | ||
ProcartaPlex Human Exosome Characterization Panel, 6plex
| 96 tests | EPX060-15845-901 |
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation using the same sample (Figure 5).
Learn more about QuantiGene RNA assays for Gene Expression Profiling
Read our publication: Multiplexing protein and gene level measurements on a single Luminex platform. Methods, 2019. 158: 27-32.
Figure 5. Combined workflow for QuantiGene gene expression and ProcartaPlex protein quantitation assays.
In complement to the existing ProcartaPlex panels for immune response profiling, researchers can now perform gene expression profiling using the same sample and instrument. For example, the preconfigured QuantiGene Plex Human Immune Response Panel, 80-plex simultaneously analyzes 80 cytokine, chemokine, and growth factor targets allowing researchers to obtain a fully characterized profile at both the RNA and protein level (Figure 6).
Additional panels are also available for curated research into immune profiling and cancer biomarkers across human and mice samples (Table 4).
Product name | Size | Cat. No. |
QuantiGene Plex Human Immune Response Panel, 80-plex Targets: CCL1, CCL13, CCL17 ,CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL4, CCL7, CCL8, CD40LG, CSF1, CSF2, CSF3, CX3CL1,CXCL1, CXCL11, CXCL13, CXCL2, CXCL5, CXCL6, CXCL9, CXCR3, FGF2, GZMA, GZMB, HGF, IFNA1, IFNG, IL10, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL18, IL1A, IL1B, IL2, IL20, IL21, IL22, IL23A, IL27, IL2RA, IL3, IL31, IL34, IL37, IL4, IL5, IL6, IL8, IL9, KITLG, LGALS3, LIF, LTA, MIF, NGF, PTX3, TNF, TNFRSF12A, TNFRSF1B, TNFRSF8, TNFSF10, TNFSF13, TNFSF13B, TREM1, TSLP, VEGFA, PPIB, HPRT1, GAPDH, GUSB | 1 plate | QGP-180-10080 |
3 plates | ||
10 plates | ||
QuantiGene Plex Mouse Immune Response Panel, 80-plex Targets: Il2ra, Il2, Il6, Ifng, Tnf, Il5, Il1a, Csf2, Il4, Il10, Il18, Vegfa, Il17a, Il1b, Il12a, Ccl2, Ccl7, Ccl11, Ccl5, Cxcl11, Il6ra, Ccl3, Ccl4, Il13, Il23a, Cxcr3, Il22, Il15, Il27, Il33, Ifna1, Il28a, Il31, Cxcl1, Cxcl2, Csf3, Il3, Lep, Tnfsf11, Csf1, Lif, Il9, Btc, Cxcl5, Il25, Il1rl1, Il19, Cd27, Kdr, Ccl19, Cxcl16, Il16, Ccl22, Ccl12, Gzmb, Ccl27a, Ccl24, Ccl17, Ccl25, Cxcl13, Il7r, Il7, Tslp, Tnfsf13b, Il12b, Il21, Gzma, Cd274, Ctla4, Cxcl9, Havcr2, Lag3, Ifna2, Ifnb1, Hgf, Tnfrsf12a, Ppib, Hprt, Gapdh, Gusb | 1 plate | |
3 plates | ||
10 plates | ||
QuantiGene Plex Human PanCancer Panel, 80-plex Targets: AGER, ARG1, AXL, BDNF, BTLA, CALR, CD27, CD274, CD276, CD28, CD36, CD47, CD48, CD80, CD96, CDH1, CSF3, CTLA4, CXCL8, DKK1, EGF, EPCAM, FGF2, GAPDH, GAS6, GPC1, GUSB, HAVCR2, HGF, HMGB1, HPRT1, HSP90AA1, HSPA4, HSPB2, HSPD1, ICOSLG, IDO1, IGF2, KITLG, LAG3, LGALS9, LIF, MBL2, MDK, MERTK, MICA, MICB, NCR3LG1, NECTIN2, NGF, NT5E, NTRK2, OLR1, PDCD1LG2, PECAM1, PGF, PLAUR, PPIB, PRF1, PVR, RAET1E, S100A8, S100A9, SERPINE1, SIGLEC7, SIGLEC9, SPARC, SPATA2, TIMD4, TNFRSF14, TNFRSF18, TNFRSF4, TNFRSF9, TRIM8, TYRO3, ULBP1, ULBP3, VEGFA, VEGFD, VSIR | 1 plate | |
3 plates | ||
10 plates | ||
QuantiGene Plex Mouse PanCancer Panel, 80-plex Targets: Ager, Arg1, Axl, Bdnf, Btla, Calr, Cd27, Cd274, Cd276, Cd28, Cd36, Cd47, Cd48, Cd80, Cd96, Cdh1, Csf3, Ctla4, Cxcl1, Dkk1, Egf, Epcam, Fgf2, Gapdh, Gas6, Gpc1, Gusb, Havcr2, Hgf, Hmgb1, Hprt, Hsp90Aa1, Hspa4, Hspb2, Hspd1, Icosl, Ido1, Igf2, Inhca , Kitl, Lag3, Lgals9, Lif, Mbl2, Mdk, Mertk, Mill2, Ncr1, Nectin2, Ngf, Nt5E, Ntrk2, Olr1, Pdcd1Lg2, Pecam1, Pgf, Plaur, Ppib, Prf1, Pvr, Raet1E, S100A8, S100A9, Serpine1, Siglece, Siglech, Sparc, Spata2, Timd4, Tnfrsf14 , Tnfrsf18, Tnfrsf4, Tnfrsf9, Trim8, Tyro3, Ulbp1, Ulbp3, Vegfa, Vegfd, Vsir | 1 plate | |
3 plates | ||
10 plates |
Cancer is a leading cause of death worldwide and has become a major public health issue in the developed countries. Cancer development is a multistep process, during which the cells accumulate genetic abnormalities, especially in oncogenes and tumor suppressor genes, contributing to uncontrolled proliferation. These abnormalities provide several growth advantages. Indeed, the transformation from normal cell to tumor cell frequently involves mutations in the cell genome.
Hanahan and Weinberg described six key changes that occur during the transformation from a normal cell to a tumor cell; these features may be considered hallmarks of cancer. These comprise of sustaining proliferative signaling, evading growth suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, disrupting metabolism, and avoiding immune destruction [1] (Figure 1).
Four additional hallmarks and characteristics have been proposed by Hanahan, and these could be considered as part of the core hallmarks of cancer (Figure 1). More recently it has become evident that the cancer cell-derived extracellular vesicles/exosomes and their molecular cargo are implicated in almost all hallmarks of cancer as critical mediators of inter-cellular communication [1]. It has also been recognized that the tumor microenvironment plays a large critical part in tumorigenesis and malignant progression [2].
Figure 1. The biological processes established during the development of human tumors.
Expression of proliferation and survival signals by tumor cells allows them to grow continually as immortalized cells. To achieve growth independent of external growth factors, some tumor cells express activating mutations in proteins involved in cell growth. With a reduced dependence on exogenous growth signals, cancer cells can disrupt homeostasis and rapidly proliferate [3]. For example, ~50% of melanomas bear mutations in the gene coding for the serine-threonine kinase BRAF, and among these, about 90% are V600E point mutations [4].
With the ability to evade growth-inhibiting checkpoints, cancer cells can proliferate rapidly without suppression. Some of the most common tumor suppressants circumvented by cancer cells include signals of p53, retinoblastoma proteins, and transforming growth factor-beta (TGF-β) [5].
Retinoblastoma-associated proteins are responsible for regulating cells through growth-and-division cycles, whereas p53 proteins get signals from stress and abnormality sensors and can either halt cell-cycle progression or trigger apoptosis. In late-stage tumors, TGF-β can be found to activate cellular programs that confer traits to cancer cells associated with high-grade malignancy [1].
Approximately 90% of human cancer deaths are due to metastases, which are caused through invasion of adjacent tissues from the primary tumor site. A complex process, both invasion and metastasis involve utilizing changes in the physical coupling of cells to their environments and activation of extracellular proteases. Cell-cell adhesion molecules (CAMs), such as certain immunoglobulins, cadherins, and integrins, play a critical role in cancer cells invading and metastasizing new sites. E-cadherin is an example of a CAM that frequently observes downregulation and mutational inactivation in carcinomas [1].
A hallmark to many cancers, acquired resistance to apoptosis is a key feature in the survival and growth of cancer cells. Tumor cells limit apoptosis through the loss of p53 function, increased expression of antiapoptotic regulators or survival signals, or by downregulation of proapoptotic factors. This demonstrates that cancer cells operate diverse apoptosis-evading mechanisms during progression to malignancy [1].
Some targets associated in cell death include danger-associated molecular patterns which are released upon cell stress (HSP70, HSP90), HMGB1 in response to anti-cancer therapy and immunogenic cell death, and DKK1 which is secreted to regulate cell survival via the WNT signaling pathway.
Although not fully characterized, evading immunological destruction by T and B lymphocytes, macrophages, and natural killer (NK) cells is considered a new emerging hallmark of cancer. While the immune system acts as a significant barrier to tumor formation, under certain conditions (such as immunodeficient/immunocompromised state), the tumors can form more frequently and grow quicker. Furthermore, immunogenic cells can disable or paralyze T lymphocytes or NK cells—evading the immune system [1].
It has also been noted that certain inflammatory responses (such as infections or wound healing) have the inadvertent effect of supporting tumor functions. For example, inflammation can supply tumor microenvironments with growth and survival factors, and various enzymes that facilitate angiogenesis and aid in invasion and metastasis [1].
Some tumor cells overexpress vascular endothelial growth factor (VEGF), which is a major angiogenic factor. Secretion of angiogenic factors such as VEGF by tumor cells create blood vessels, which provide nutrients to the interior of tumors. These blood vessels are architecturally different from normal blood vessels being less organized. In order to grow, the tumors need to have blood supply to their interior, for delivery of nutrients and O2. The process of blood vessel growth is called angiogenesis, and most solid tumors secrete angiogenic factors [3].
Cancer cell-derived exosomes have emerged as a novel class of biomarkers playing a significant role in almost all hallmarks of cancer. As crucial mediators of inter-cellular communication, they transfer their molecular cargo from the releasing cell to the recipient cell. Recent advances have particularly focused on cancer cell-derived exosomes that contribute to tumorigenic and metastatic processes. This is achieved by shaping the tumor microenvironment, which is a valuable source of biomarkers in liquid biopsies [6].
Exosomes are secreted by almost all cell types, including cancerous cells. Tumor-derived exosomes have been reportedly involved in cancer malignancy by supporting proliferation, establishing pre-metastatic niches, and regulating drug resistance. They can also assist in the regulation and mediation of organotrophic metastasis, re-education of stromal cells, endocrine/paracrine induction of cancers, angiogenesis activation, immune system modulation, and remodeling of the extracellular matrix [6].
Learn more about cancer research areas and methods
ELISA enables the detection and measurement of a wide assortment of markers that fall within the hallmarks of cancer. This allows further investigation into cancer progression using various biological sources. We offer ELISA kits for the study of important targets that are useful for cancer research, from growth factors to immune-oncology checkpoints.
Invitrogen ELISA kits for popular targets such as EGF, IL-8, VEGF etc. are listed in Table 1. Standard curve of Human IL-8/NAP-1 using IL-8 Human ELISA Kit is shown in Figure 2.
Search cancer-related ELISA kits
Learn more about ELISA kits and components
Figure 2. Representative standard curve for Human IL-8/NAP-1 ELISA. ELISA was performed using human interleukin 8 (Hu IL-8) ranging from 0–1,000 pg/ml (0, 15.6, 31.2, 62.5, 125, 250, 500, and 1,000 pg/ml) and IL-8 Human ELISA Kit. Absorbance was measured at 450 nm and standard curve was plotted.
ProQuantum high-sensitivity immunoassays are designed for ease-of-use, high performance protein detection without the need for specialized instruments. Utilizing proximity-based amplification technology, these assays combine analyte specific high-affinity antibody-antigen binding with signal detection and amplification capabilities of qPCR to achieve a simple yet powerful next-generation protein quantitation platform.
These assays can be used to detect low target levels while using a smaller volume of sample, which is beneficial when handling limited precious samples. Invitrogen ProQuantum immunoassay kits for popular targets such as EGF, IL-8, c-Met etc. are listed in Table 2. Standard curve of EGF using EGF Human ProQuantum Immunoassay Kit is shown in Figure 3.
Find cancer-related ProQuantum assays
Learn more about how the ProQuantum immunoassays work
Read BioProbes Journal article: Introducing ProQuantum High-Sensitivity Immunoassays—The new generation of target-specific protein quantitation
Figure 3. Examples of Human EGF standard curve. The standard curve for EGF Human ProQuantum Immunoassay Kit shows a large dynamic range (0.00256–5,000 pg/mL) for EGF protein.
Invitrogen ProcartaPlex multiplex immunoassay panels provide a powerful biomarker detection tool to help distinguish diseased from non-diseased states and probe cellular processes involved with cancer progression. These Luminex xMAP-based assays allow for the simultaneous measurement and tracking of multiple soluble proteins and targets of interest over time to thoroughly understand markers in cancer development and metastasis. Various checkpoint markers in melanoma patient samples were measured using the ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex and ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex (Figure 4).
Select one of our preconfigured panels described in Table 3 or use the Panel Configurator below to customize your specific panel.
ProcartaPlex Panel Configurator
Learn more about ProcartaPlex multiplex immunoassays
Figure 4. Serum levels of checkpoint markers in melanoma patient samples. The ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex and ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex were used to measure various checkpoint markers in melanoma patient samples. Results are shown as the mean of ungrouped human samples for all targets of both the panels. Used with permission from Exner R., Sachet M., Arnold T., et al. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med, 2016. 5(9): 2350-8.
Sustaining Proliferative Signaling Panel | ||
---|---|---|
Product name | Size | Cat. No. |
ProcartaPlex Human Cell Proliferation Panel, 8plex Target list [bead region]: | 96 tests | EPX080-15844-901 |
Evading growth suppressors | ||
ProcartaPlex Human Growth Factor Panel, 11plex Target list [bead region]: | 96 tests | EPX110-12170-901 |
Activating invasion and apoptosis | ||
ProcartaPlex Human Cell Proliferation and Metastasis Panel 1, 13plex Target list [bead region]: | 96 tests | EPX130-15841-901 |
ProcartaPlex Human Cell Proliferation and Metastasis Panel 2, 12plex Target list [bead region]: beta-2-microglobulin (B2M) [21], cathepsin D [44], CEA (CEACAM-5) [52], EGFR (ErbB1) [37], haptoglobin [63], HGFR (c-Met) [25], IGFBP-2 [76], IGFBP-3 [13], MIA [75], MIP-4 (CCL18) [61], periostin (OSF-2) [62], VE-cadherin [28] | 96 tests | EPX120-15842-901 |
Resisting cell death | ||
ProcartaPlex Human Cell Death Panel, 4plex Target list [bead region]: | 96 tests | EPX040-15843-901 |
ProcartaPlex Human Apoptotic Cell Clearance Panel, 12plex Target list [bead region]: | 96 tests | EPX120-15816-901 |
Avoiding immune destruction/tumor promoting inflammation | ||
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 1, 14plex Target list [bead region]: | 96 tests | EPX14A-15803-901 |
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 2, 14plex Target list [bead region]: | 96 tests | EPX140-15815-901 |
ProcartaPlex Human Immuno-Oncology Checkpoint Panel 3, 9plex Target list [bead region]: | 96 tests | EPX090-15820-901 |
Inducing Angiogenesis | ||
ProcartaPlex Human Angiogenesis Panel, 18plex Target list [bead region]: | 96 tests | EPX180-15806-901 |
ProcartaPlex Human Angiogenesis Panel 2, 3plex Target list [bead region]: | 96 tests | EPX030-15807-901 |
Cancer cell-derived exosomes | ||
ProcartaPlex Human Exosome Characterization Panel, 6plex
| 96 tests | EPX060-15845-901 |
QuantiGene RNA gene expression assays provide a fast and high-throughput solution for multiplexed gene expression quantitation, with simultaneous measurement of up to 80 genes of interest in a single well of a 96- or 384-well plate. The QuantiGene Plex assay is based on hybridization and incorporates branched DNA (bDNA) technology, which uses signal amplification rather than target amplification for direct measurement of RNA transcripts. The assay is run on the Luminex platform, has a simple workflow, and does not require RNA purification. These features allow the user to merge the QuantiGene workflow for gene expression profiling with the ProcartaPlex workflow for protein quantitation using the same sample (Figure 5).
Learn more about QuantiGene RNA assays for Gene Expression Profiling
Read our publication: Multiplexing protein and gene level measurements on a single Luminex platform. Methods, 2019. 158: 27-32.
Figure 5. Combined workflow for QuantiGene gene expression and ProcartaPlex protein quantitation assays.
In complement to the existing ProcartaPlex panels for immune response profiling, researchers can now perform gene expression profiling using the same sample and instrument. For example, the preconfigured QuantiGene Plex Human Immune Response Panel, 80-plex simultaneously analyzes 80 cytokine, chemokine, and growth factor targets allowing researchers to obtain a fully characterized profile at both the RNA and protein level (Figure 6).
Additional panels are also available for curated research into immune profiling and cancer biomarkers across human and mice samples (Table 4).
Product name | Size | Cat. No. |
QuantiGene Plex Human Immune Response Panel, 80-plex Targets: CCL1, CCL13, CCL17 ,CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL4, CCL7, CCL8, CD40LG, CSF1, CSF2, CSF3, CX3CL1,CXCL1, CXCL11, CXCL13, CXCL2, CXCL5, CXCL6, CXCL9, CXCR3, FGF2, GZMA, GZMB, HGF, IFNA1, IFNG, IL10, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL18, IL1A, IL1B, IL2, IL20, IL21, IL22, IL23A, IL27, IL2RA, IL3, IL31, IL34, IL37, IL4, IL5, IL6, IL8, IL9, KITLG, LGALS3, LIF, LTA, MIF, NGF, PTX3, TNF, TNFRSF12A, TNFRSF1B, TNFRSF8, TNFSF10, TNFSF13, TNFSF13B, TREM1, TSLP, VEGFA, PPIB, HPRT1, GAPDH, GUSB | 1 plate | QGP-180-10080 |
3 plates | ||
10 plates | ||
QuantiGene Plex Mouse Immune Response Panel, 80-plex Targets: Il2ra, Il2, Il6, Ifng, Tnf, Il5, Il1a, Csf2, Il4, Il10, Il18, Vegfa, Il17a, Il1b, Il12a, Ccl2, Ccl7, Ccl11, Ccl5, Cxcl11, Il6ra, Ccl3, Ccl4, Il13, Il23a, Cxcr3, Il22, Il15, Il27, Il33, Ifna1, Il28a, Il31, Cxcl1, Cxcl2, Csf3, Il3, Lep, Tnfsf11, Csf1, Lif, Il9, Btc, Cxcl5, Il25, Il1rl1, Il19, Cd27, Kdr, Ccl19, Cxcl16, Il16, Ccl22, Ccl12, Gzmb, Ccl27a, Ccl24, Ccl17, Ccl25, Cxcl13, Il7r, Il7, Tslp, Tnfsf13b, Il12b, Il21, Gzma, Cd274, Ctla4, Cxcl9, Havcr2, Lag3, Ifna2, Ifnb1, Hgf, Tnfrsf12a, Ppib, Hprt, Gapdh, Gusb | 1 plate | |
3 plates | ||
10 plates | ||
QuantiGene Plex Human PanCancer Panel, 80-plex Targets: AGER, ARG1, AXL, BDNF, BTLA, CALR, CD27, CD274, CD276, CD28, CD36, CD47, CD48, CD80, CD96, CDH1, CSF3, CTLA4, CXCL8, DKK1, EGF, EPCAM, FGF2, GAPDH, GAS6, GPC1, GUSB, HAVCR2, HGF, HMGB1, HPRT1, HSP90AA1, HSPA4, HSPB2, HSPD1, ICOSLG, IDO1, IGF2, KITLG, LAG3, LGALS9, LIF, MBL2, MDK, MERTK, MICA, MICB, NCR3LG1, NECTIN2, NGF, NT5E, NTRK2, OLR1, PDCD1LG2, PECAM1, PGF, PLAUR, PPIB, PRF1, PVR, RAET1E, S100A8, S100A9, SERPINE1, SIGLEC7, SIGLEC9, SPARC, SPATA2, TIMD4, TNFRSF14, TNFRSF18, TNFRSF4, TNFRSF9, TRIM8, TYRO3, ULBP1, ULBP3, VEGFA, VEGFD, VSIR | 1 plate | |
3 plates | ||
10 plates | ||
QuantiGene Plex Mouse PanCancer Panel, 80-plex Targets: Ager, Arg1, Axl, Bdnf, Btla, Calr, Cd27, Cd274, Cd276, Cd28, Cd36, Cd47, Cd48, Cd80, Cd96, Cdh1, Csf3, Ctla4, Cxcl1, Dkk1, Egf, Epcam, Fgf2, Gapdh, Gas6, Gpc1, Gusb, Havcr2, Hgf, Hmgb1, Hprt, Hsp90Aa1, Hspa4, Hspb2, Hspd1, Icosl, Ido1, Igf2, Inhca , Kitl, Lag3, Lgals9, Lif, Mbl2, Mdk, Mertk, Mill2, Ncr1, Nectin2, Ngf, Nt5E, Ntrk2, Olr1, Pdcd1Lg2, Pecam1, Pgf, Plaur, Ppib, Prf1, Pvr, Raet1E, S100A8, S100A9, Serpine1, Siglece, Siglech, Sparc, Spata2, Timd4, Tnfrsf14 , Tnfrsf18, Tnfrsf4, Tnfrsf9, Trim8, Tyro3, Ulbp1, Ulbp3, Vegfa, Vegfd, Vsir | 1 plate | |
3 plates | ||
10 plates |
For Research Use Only. Not for use in diagnostic procedures.